Elorac, Inc., a biopharmaceutical company focused on developing first-in-class and best-in-class innovative dermatology products, today announced that data from its Phase 2 trial evaluating the safety and efficacy of its patented once-weekly acne treatment for severe nodulocystic acne will be presented at the Society For Investigative Dermatology (SID) Annual Meeting being held in Orlando May 16-19, 2018. The SID meeting is an important international meeting that allows dermatologists to discuss the latest research advancements in dermatology. “We are pleased to have an opportunity to present our data to the dermatologic community, and believe that this late-stage program offers a promising alternative to isotretinoin for treatment of nodulocystic acne,” said Joel Bernstein, M.D., Executive Chairman of Elorac.
The Investigative Dermatology Meeting is organized jointly every five years by the world’s pre-eminent skin health research organizations from Europe (European Society for Dermatological Research), Asia (The Japanese Society for Investigative Dermatology) and North America (Society of Investigative Dermatology) to bring together the world’s finest physicians, scientists and researchers in the fields of cutaneous biology, dermatology and related disciplines.
About Elorac, Inc.
Elorac, Inc. is a privately owned, specialty pharmaceutical company engaged in the development and commercialization of novel products for dermatology, allergy and oncology. Elorac’s development pipeline includes: naloxone lotion for treatment of pruritus accompanying cutaneous T-cell lymphoma, a product with orphan drug and fast-track designations from the U.S. Food and Drug Administration; cidoxepin, a highly potent histamine H1-receptor antagonist being developed for relief of chronic urticaria; and a once-weekly non-retinoid tablet for nodulocystic acne.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180517005738/en/
Contacts:
Barry Hollingsworth
847-362-8200 ext. 230
barry@eloracpharma.com
